Faster than traditional drug development.


Wetlab experiments. Patients needed until P2.


Better models than PRS.


Assets currently in development in pipeline.


See What We’ve Been Up To

Mon Oct 04 2021

Treatment for COVID-19 Ready for Clinical Trials Phase 2b

Our treatment aims to prevent the dangerous overreaction of the immune system that results in patients becoming critically ill due to COVID-19. Using Biobank data, we identified CDK6 as a drug target. Inhibiting it will lower neutrophil cell count, which, when too high, is strongly linked with the severe and critical course of COVID-19. This potential treatment has been endorsed by Key Opionion Leaders from Harvard Medical School, Germany’s Robert-Koch-Institute and the University of Marburg. We are preparing a clinical phase 2b trial to show efficacy.

Tue Oct 05 2021

Biotx BEYOND Webinar 2

In our latest webinar we discuss the future of clinical trials. John Zibert, CEO of Studies&Me talks about how his company conducts decentralized, virtual clinical trials. Our own Justin Cope then presents the technology behind biotx.ai, which is able to discover drug targets with a high likelihood of success in clinical trials.